No end in sight, China seeks new weapons in COVID-19 struggle

7 November 2022
china_flag_big

Biopharmaceutical firms in China are focusing on the development of new COVID-19 treatments, designed to tackle new Omicron variants.

While much of the developed world has moved on from the acute phase of the coronavirus pandemic, China has to some extent been a victim of its own success in stopping the initial waves of infection.

As a result, the country is believed to have relatively low levels of natural immunity, while homegrown vaccines such as CanSino Biologics’ (SSE: 688185) Convidecia do not have the same level of efficacy as mRNA-based jabs developed abroad.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology